<DOC>
	<DOCNO>NCT01168882</DOCNO>
	<brief_summary>The purpose study determine safety tolerability RGB-286638 , novel , multi-targeted kinase inhibitor , administer patient select , relapsed refractory hematological malignancy .</brief_summary>
	<brief_title>Safety Tolerability RGB-286638 Patients With Selected , Relapsed Refractory Hematological Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Histologically/cytologically confirm diagnosis : Multiple myeloma ( MM ) Chronic Lymphocytic Leukemia ( CLL ) / Small Lymphocytic Lymphoma ( SLL ) Mantle Cell Lymphoma ( MCL ) Chronic Myelogenous Leukemia ( CML ) Refractory to/relapsed and/or intolerant one standard therapies standard therapy exists . ECOG performance status 02 . Adequate bone marrow , cardiovascular , renal hepatic function Recovery adverse event due prior therapy Contraception Prior chemotherapy , monoclonal antibody , investigational agent , radiation therapy ( involve ≥ 30 % active bone marrow ) within 14 day prior first dose ( note nitrosoureas mitomycin permit least 42 day first dose RGB286638 ) . CNS involvement hematological malignancy . Active unstable cardiac disease and/or history myocardial infarction within 6 month and/or history clinically significant ventricular arrhythmia . Concomitant therapy know prolong QT interval associate risk Torsades de Pointes ( TdP ) permit within 7 day first dose ; however , amiodarone permit within 90 day first dose . Patients uncontrolled unstable intercurrent illness . Concomitant therapy inhibitor and/or inducer CYP450 3A4 within 1 week first dose . Bleeding disorder unrelated hematological malignant disease . HIV HIVrelated malignancy . History malignancy except : ( ) adequately treat basal squamous cell carcinoma skin ; ( ii ) curatively treat , ) situ carcinoma uterine cervix , b ) prostate cancer , c ) superficial bladder cancer ; ( iii ) curatively treat solid tumor evidence disease ≥ 2 year . Any condition would , investigator 's judgment , contraindicate patient 's participation clinical study due safety concern compliance clinical study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>RGB-286638</keyword>
	<keyword>Hematological Malignancies</keyword>
</DOC>